Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy

J. R. Mendell, R. T. Moxley, R. C. Griggs, M. H. Brooke, G. M. Fenichel, J. P. Miller, W. King, L. Signore, S. Pandya, J. Florence, J. Schierbecker, J. Robison, K. Kaiser, S. Mandel, C. Arfken, B. Gilder

Research output: Contribution to journalArticlepeer-review

417 Scopus citations

Abstract

We performed a randomized, double-blind, controlled six-month trial of prednisone in 103 boys with Duchenne's muscular dystrophy (age, 5 to 15 years). The patients were assigned to one of three regimens: prednisone, 0.75 mg per kilogram of body weight per day (n = 33); prednisone, 1.5 mg per kilogram per day (n = 34); or placebo (n = 36). The groups were initially comparable in all measures of muscle function. Both prednisone groups had significant improvement of similar degree in the summary scores of muscle strength and function. Improvement began as early as one month and peaked by three months. At six months the high-dose prednisone group, as compared with the placebo group, had improvement in the time needed to rise from a supine to a standing position (3.4 vs. 6.2 seconds), to walk 9 m (7.0 vs. 9.7 seconds), and to climb four stairs (4.0 vs. 7.1 seconds), in lifting a weight (2.1 vs. 1.2 kg), and in forced vital capacity (1.7 vs. 1.5 liters) (P<0.001 for all comparisons). There was an increase in urinary creatinine excretion (261 vs. 190 mg per 24 hours), which suggested an increase in total muscle mass. However, the prednisone-treated patients who had required long-leg braces (n = 5) or wheelchairs (n = 11) continued to require them. The most frequent side effects were weight gain, cushingoid appearance, and excessive hair growth. We conclude from this six-month study that prednisone improves the strength and function of patients with Duchenne's muscular dystrophy. However, further research is required to identify the mechanisms responsible for these improvements and to determine whether prolonged treatment with corticosteroids may be warranted despite their side effects. DUCHENNE'S muscular dystrophy is an inexorably progressive disease that results in severe disability by the age of 10 to 12 years and in death in early adulthood. Despite recent major advances in the understanding of the molecular genetic defect,1 2 3 4 5 6 no treatment improves or even slows the disorder. We recently observed an increase in muscle strength after six months of prednisone treatment (1.5 mg per kilogram of body weight per day) in an open therapeutic trial in 33 patients with Duchenne's muscular dystrophy.7 That study, which used historical controls,8 suggested that patients with this disorder received a short-term benefit. However, that…

Original languageEnglish
Pages (from-to)1592-1597
Number of pages6
JournalNew England Journal of Medicine
Volume320
Issue number24
DOIs
StatePublished - Jun 15 1989

Fingerprint

Dive into the research topics of 'Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy'. Together they form a unique fingerprint.

Cite this